Eevia Health Plc, a pioneer in the production of organic plant extracts, has announced a series of new sales orders worth KEUR 66 this week. This development marks an exciting phase for the company as it continues to expand its footprint in the global health market.

The orders include KEUR 11 from a French partner and KEUR 8 from another European customer for Eevia's Feno-Myrtillus 25, a bilberry extract. Notably, the European customer intends to use the bilberry extract in animal feed, representing a high-volume opportunity. Additionally, a Finnish customer has placed an order for KEUR 10 of bilberry products, while Select Ingredients has ordered bilberry products for a US-based organic brand.

Furthermore, Eevia received a KEUR 7 order for Fenoprolic 70 Organic from another Finnish customer, and a KEUR 10 order from a German customer through distributor Breko. In the US, orders were placed for Feno-Chaga Organic via distributor NutriOriginal, and a small initial order for Feno-Ceraus 5 Organic, a tart cherry extract. A new Latvian customer also joined the roster with a KEUR 3 order for bilberry extract.

These orders, primarily channeled through distributors, support end customers in building high-quality natural brands. With the exception of Feno-Ceraus 5, all products are in stock, allowing for immediate delivery, which positively impacts cash flow. Eevia also has the raw material for Feno-Ceraus 5 and can produce it quickly, ensuring no delay in fulfilling customer needs.

Founded in 2017, Eevia Health focuses on addressing global health challenges through bioactive compounds sustainably extracted from renewable plant materials. The company operates a modern green-chemistry production facility in Finland, ensuring a short value chain and a minimal environmental footprint.

Given the strategic positioning of Eevia Health in the organic plant extract market and the growing demand for natural health products, the company's recent orders underscore its potential for sustained growth. Investors might consider holding their position in Eevia Health, as these developments indicate a promising trajectory for the company.